A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Alisertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 25 Jan 2018 Last checked against ClinicalTrials.gov record.
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated